Nuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) major shareholder Marlio Charles Mosseri acquired 5,399 shares of the business's stock in a transaction that occurred on Tuesday, June 17th. The stock was purchased at an average cost of $8.11 per share, with a total value of $43,785.89. Following the acquisition, the insider now directly owns 2,948,160 shares of the company's stock, valued at $23,909,577.60. This trade represents a 0.18% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Major shareholders that own at least 10% of a company's shares are required to disclose their sales and purchases with the SEC.
Marlio Charles Mosseri also recently made the following trade(s):
- On Wednesday, June 18th, Marlio Charles Mosseri acquired 28,043 shares of Nuvectis Pharma stock. The stock was purchased at an average cost of $8.05 per share, with a total value of $225,746.15.
- On Monday, May 12th, Marlio Charles Mosseri acquired 21,167 shares of Nuvectis Pharma stock. The stock was purchased at an average cost of $8.11 per share, with a total value of $171,664.37.
- On Thursday, May 8th, Marlio Charles Mosseri acquired 2,650 shares of Nuvectis Pharma stock. The stock was purchased at an average cost of $8.65 per share, with a total value of $22,922.50.
- On Tuesday, May 6th, Marlio Charles Mosseri acquired 12,444 shares of Nuvectis Pharma stock. The stock was purchased at an average cost of $8.59 per share, with a total value of $106,893.96.
Nuvectis Pharma Price Performance
Shares of NASDAQ NVCT traded up $0.08 during mid-day trading on Friday, reaching $8.13. The company's stock had a trading volume of 93,851 shares, compared to its average volume of 129,786. The firm has a market capitalization of $169.84 million, a PE ratio of -7.19 and a beta of -0.16. The stock has a fifty day moving average of $9.28 and a two-hundred day moving average of $7.68. Nuvectis Pharma, Inc. has a 52 week low of $4.44 and a 52 week high of $11.80.
Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.27) earnings per share for the quarter, topping analysts' consensus estimates of ($0.30) by $0.03. Analysts anticipate that Nuvectis Pharma, Inc. will post -1.01 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several analysts have issued reports on NVCT shares. Laidlaw started coverage on Nuvectis Pharma in a report on Monday, March 17th. They set a "buy" rating and a $19.00 price target for the company. HC Wainwright reissued a "buy" rating and set a $15.00 price target (up previously from $11.00) on shares of Nuvectis Pharma in a report on Wednesday, April 30th. Finally, Maxim Group started coverage on Nuvectis Pharma in a report on Wednesday, April 2nd. They set a "buy" rating and a $17.00 price target for the company.
Check Out Our Latest Stock Analysis on NVCT
Hedge Funds Weigh In On Nuvectis Pharma
A number of hedge funds have recently made changes to their positions in NVCT. Cubist Systematic Strategies LLC bought a new position in shares of Nuvectis Pharma in the fourth quarter worth about $34,000. Baxter Bros Inc. boosted its stake in shares of Nuvectis Pharma by 20.0% in the fourth quarter. Baxter Bros Inc. now owns 15,000 shares of the company's stock worth $81,000 after acquiring an additional 2,500 shares during the period. Blue Zone Wealth Advisors LLC purchased a new stake in shares of Nuvectis Pharma in the first quarter worth about $102,000. Squarepoint Ops LLC purchased a new stake in shares of Nuvectis Pharma in the fourth quarter worth about $103,000. Finally, Oppenheimer & Co. Inc. purchased a new stake in shares of Nuvectis Pharma in the fourth quarter worth about $135,000. Institutional investors own 96.77% of the company's stock.
About Nuvectis Pharma
(
Get Free Report)
Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.
Featured Articles
Before you consider Nuvectis Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nuvectis Pharma wasn't on the list.
While Nuvectis Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
